PMID- 15825167
OWN - NLM
STAT- MEDLINE
DCOM- 20050824
LR  - 20220318
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 116
IP  - 4
DP  - 2005 Sep 10
TI  - Intratumoral injection of immature dendritic cells enhances antitumor effect of 
      hyperthermia using magnetic nanoparticles.
PG  - 624-33
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that play a pivotal 
      role in regulating immune responses in cancer and have recently been shown to be 
      activated by heat shock proteins (HSPs). We previously reported that HSP70 
      expression after hyperthermia induces antitumor immunity. Our hyperthermia system 
      using magnetite cationic liposomes (MCLs) induced necrotic cell death that was 
      correlated with HSP70 release. In the present study, we investigated the 
      therapeutic effects of DC therapy combined with MCL-induced hyperthermia on mouse 
      melanoma. In an in vitro study, when immature DCs were pulsed with mouse B16 
      melanoma cells heated at 43 degrees C, major histocompatibility complex (MHC) 
      class I/II, costimulatory molecules CD80/CD86 and CCR7 in the DCs were 
      upregulated, thus resulting in DC maturation. C57BL/6 mice bearing a melanoma 
      nodule were subjected to combination therapy using hyperthermia and DC 
      immunotherapy in vivo by means of tumor-specific hyperthermia using MCLs and 
      directly injected immature DCs. Mice were divided into 4 groups: group I 
      (control), group II (hyperthermia), group III (DC therapy) and group IV 
      (hyperthermia + DC therapy). Complete regression of tumors was observed in 60% of 
      mice in group IV, while no tumor regression was seen among mice in the other 
      groups. Increased cytotoxic T lymphocyte (CTL) and natural killer (NK) activity 
      was observed on in vitro cytotoxicity assay using splenocytes in the cured mice 
      treated with combination therapy, and the cured mice rejected a second challenge 
      of B16 melanoma cells. This study has important implications for the application 
      of MCL-induced hyperthermia plus DC therapy in patients with advanced 
      malignancies as a novel cancer therapy.
CI  - (c) 2005 Wiley-Liss, Inc.
FAU - Tanaka, Kouji
AU  - Tanaka K
AD  - Department of Biotechnology, School of Engineering, Nagoya University, Furo-cho, 
      Chikusa-ku, Nagoya, Japan.
FAU - Ito, Akira
AU  - Ito A
FAU - Kobayashi, Takeshi
AU  - Kobayashi T
FAU - Kawamura, Tatsuyoshi
AU  - Kawamura T
FAU - Shimada, Shinji
AU  - Shimada S
FAU - Matsumoto, Kazuhiko
AU  - Matsumoto K
FAU - Saida, Toshiaki
AU  - Saida T
FAU - Honda, Hiroyuki
AU  - Honda H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Cations)
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - 0 (Liposomes)
RN  - 0 (Oxides)
RN  - E1UOL152H7 (Iron)
RN  - XM0M87F357 (Ferrosoferric Oxide)
SB  - IM
MH  - Animals
MH  - Cations
MH  - Dendritic Cells/*immunology
MH  - Electromagnetic Phenomena
MH  - Ferrosoferric Oxide
MH  - HSP70 Heat-Shock Proteins/biosynthesis
MH  - *Hyperthermia, Induced
MH  - Iron/*therapeutic use
MH  - Liposomes
MH  - Melanoma/*therapy/veterinary
MH  - Mice
MH  - *Nanostructures
MH  - Oxides/*therapeutic use
MH  - Skin Neoplasms/*therapy/veterinary
MH  - T-Lymphocytes, Cytotoxic
EDAT- 2005/04/13 09:00
MHDA- 2005/08/25 09:00
CRDT- 2005/04/13 09:00
PHST- 2005/04/13 09:00 [pubmed]
PHST- 2005/08/25 09:00 [medline]
PHST- 2005/04/13 09:00 [entrez]
AID - 10.1002/ijc.21061 [doi]
PST - ppublish
SO  - Int J Cancer. 2005 Sep 10;116(4):624-33. doi: 10.1002/ijc.21061.